These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1360811)

  • 1. Studies on concentrations of NA and HVA and activity of DBH in the serum from schizophrenic patients, first-degree relatives and normal subjects.
    Wei J; Ramchand CN; Hemmings GP
    Schizophr Res; 1992 Dec; 8(2):103-10. PubMed ID: 1360811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on neurochemical heterogeneity in healthy parents of schizophrenic patients.
    Wei J; Xu HM; Hemmings GP
    Schizophr Res; 1993 Aug; 10(2):173-8. PubMed ID: 8104469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diurnal changes in dopamine-beta-hydroxylase, homovanillic acid and 3-methoxy-4-hydroxyphenylglycol in serum of man.
    Markianos E; Backman H
    J Neural Transm; 1976; 39(1-2):79-93. PubMed ID: 988114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the relationship between the DBH activity in serum and a MspI polymorphic site in intron 9 of the human DBH gene in schizophrenia.
    Wei J; Ramchand CN; Hemmings GP
    Schizophr Res; 1996 Oct; 22(1):77-80. PubMed ID: 8908693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF dopamine beta-hydroxylase in schizophrenia.
    Sternberg DE; van Kammen DP; Lerner P; Ballenger JC; Marder SR; Post RM; Bunney WE
    Arch Gen Psychiatry; 1983 Jul; 40(7):743-7. PubMed ID: 6134515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analysis of monoamine indices in patients with chronic schizophrenia.
    Frecska E; Bagdy G; Perenyi A; Arato M; Degrell I; Mogyorosy Z
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):291-5. PubMed ID: 2577713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
    Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
    Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum homovanillic acid levels in schizophrenic patients and normal control subjects.
    Steinberg JL; Garver DL; Moeller FG; Raese JD; Orsulak PJ
    Psychiatry Res; 1993 Aug; 48(2):93-106. PubMed ID: 8416025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of indices of central dopaminergic functions in man.
    Bagdy G; Arató M; Baraczka K; Fekete MI
    Life Sci; 1983 Jun; 32(23):2667-76. PubMed ID: 6855463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.
    Kirch DG; Jaskiw G; Linnoila M; Weinberger DR; Wyatt RJ
    Psychiatry Res; 1988 Sep; 25(3):233-42. PubMed ID: 2903509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia.
    Baron M; Gruen R; Levitt M; Kane J
    Neuropsychobiology; 1982; 8(6):312-4. PubMed ID: 6131392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic antecedents of dopamine dysfunction in schizophrenia.
    Amin F; Silverman JM; Siever LJ; Smith CJ; Knott PJ; Davis KL
    Biol Psychiatry; 1999 May; 45(9):1143-50. PubMed ID: 10331106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free and conjugated plasma homovanillic acid in schizophrenic patients.
    Garcia A; Galinowski A; Guicheney P; Mignot E; Loo H; Meyer P
    Biol Psychiatry; 1989 May; 26(1):87-96. PubMed ID: 2720023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia.
    Wieselgren IM; Lindström LH
    Psychiatry Res; 1998 Nov; 81(2):101-10. PubMed ID: 9858027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.